Role of the intestinal microbiome in liver disease

Journal of Autoimmunity

Volumn 46, Issue , 2013, Pages 66-73

  Henao Mejia, Jorge ^a   Elinav, Eran ^b   Thaiss, Christoph A ^b   Licona Limon, Paula ^a   Flavell, Richard A ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Innate immune system; Microbiota; Non alcoholic fatty liver disease; Primary biliary cirrhosis

Indexed keywords

INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ALCALIGENACEAE; CHRONIC LIVER DISEASE; COMORBIDITY; DISEASE COURSE; HEPATIC ENCEPHALOPATHY; INNATE IMMUNITY; INSULIN RESISTANCE; INTESTINE FLORA; KLEBSIELLA; LACHNOSPIRACEAE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MICROBIAL COMMUNITY; NONALCOHOLIC FATTY LIVER; OBESITY; PORPHYROMONADACEAE; PREVOTELLACEAE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEUS; REVIEW; STREPTOCOCCACEAE;

INNATE IMMUNE SYSTEM; MICROBIOTA; NON-ALCOHOLIC FATTY LIVER DISEASE; PRIMARY BILIARY CIRRHOSIS;

DISEASE PROGRESSION; GASTROINTESTINAL TRACT; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INTESTINES; LIVER; LIVER DISEASES; MICROBIOTA; MODELS, IMMUNOLOGICAL;

EID: 84886284340     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.07.001     Document Type: Review

References (108)

1. Miyake Y., Yamamoto K. Role of gut microbiota in liver diseases. Hepatol Res 2012.
2. Maynard C.L., Elson C.O., Hatton R.D., Weaver C.T. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489:231-241.
3. Tremaroli V., Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489:242-249.
4. Lozupone C.A., Stombaugh J.I., Gordon J.I., Jansson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489:220-230.
5. Claesson M.J., Jeffery I.B., Conde S., Power S.E., O'Connor E.M., Cusack S., et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012, 488:178-184.
6. Turnbaugh P.J., Hamady M., Yatsunenko T., Cantarel B.L., Duncan A., Ley R.E., et al. Acore gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
7. Carvalho F.A., Aitken J.D., Vijay-Kumar M., Gewirtz A.T. Toll-like receptor-gut microbiota interactions: perturb at your own risk!. Annu Rev Physiol 2012, 74:177-198.
8. Slack E., Hapfelmeier S., Stecher B., Velykoredko Y., Stoel M., Lawson M.A., et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 2009, 325:617-620.
9. Michelsen K.S., Arditi M. Toll-like receptors and innate immunity in gut homeostasis and pathology. Curr Opin Hematol 2007, 14:48-54.
10. Visvanathan K., Skinner N.A., Thompson A.J., Riordan S.M., Sozzi V., Edwards R., et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007, 45:102-110.
11. Hosel M., Broxtermann M., Janicki H., Esser K., Arzberger S., Hartmann P., et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 2012, 55:287-297.
12. Wang B., Trippler M., Pei R., Lu M., Broering R., Gerken G., et al. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. JHepatol 2009, 51:1037-1045.
13. Yokoyama T., Komori A., Nakamura M., Takii Y., Kamihira T., Shimoda S., et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int 2006, 26:467-476.
14. Wang A.P., Migita K., Ito M., Takii Y., Daikoku M., Yokoyama T., et al. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. JAutoimmun 2005, 25:85-91.
15. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
16. Gao B., Seki E., Brenner D.A., Friedman S., Cohen J.I., Nagy L., et al. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2011, 300:G516-G525.
17. Thuy S., Ladurner R., Volynets V., Wagner S., Strahl S., Konigsrainer A., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. JNutr 2008, 138:1452-1455.
18. Mueller T., Beutler C., Pico A.H., Shibolet O., Pratt D.S., Pascher A., et al. Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int 2011, 31:1574-1588.
19. Li L., Chen L., Hu L., Liu Y., Sun H.Y., Tang J., et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011, 54:1620-1630.
20. Huang H., Shiffman M.L., Friedman S., Venkatesh R., Bzowej N., Abar O.T., et al. A7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007, 46:297-306.
21. Figueroa L., Xiong Y., Song C., Piao W., Vogel S.N., Medvedev A.E. The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF. JImmunol 2012, 188:4506-4515.
22. Petrasek J., Dolganiuc A., Csak T., Kurt-Jones E.A., Szabo G. Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. Gastroenterology 2011, 140:697-708. e4.
23. Petrasek J., Dolganiuc A., Csak T., Nath B., Hritz I., Kodys K., et al. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology 2011, 53:649-660.
24. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007, 13:1324-1332.
25. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
26. Lin Y., Yu L.X., Yan H.X., Yang W., Tang L., Zhang H.L., et al. Gut-derived lipopolysaccharide promotes T-cell-mediated hepatitis in mice through Toll-like receptor 4. Cancer Prev Res (Phila) 2012, 5:1090-1102.
27. Henao-Mejia J., Elinav E., Strowig T., Flavell R.A. Inflammasomes: far beyond inflammation. Nat Immunol 2012, 13:321-324.
28. Strowig T., Henao-Mejia J., Elinav E., Flavell R. Inflammasomes in health and disease. Nature 2012, 481:278-286.
29. Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol 2010, 22:28-33.
30. Elinav E., Strowig T., Henao-Mejia J., Flavell R.A. Regulation of the antimicrobial response by NLR proteins. Immunity 2011, 34:665-679.
31. Boaru S.G., Borkham-Kamphorst E., Tihaa L., Haas U., Weiskirchen R. Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease. JInflamm (Lond) 2012, 9:49.
32. Imaeda A.B., Watanabe A., Sohail M.A., Mahmood S., Mohamadnejad M., Sutterwala F.S., et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. JClin Invest 2009, 119:305-314.
33. Williams C.D., Farhood A., Jaeschke H. Role of caspase-1 and interleukin-1beta in acetaminophen-induced hepatic inflammation and liver injury. Toxicol Appl Pharmacol 2010, 247:169-178.
34. Watanabe A., Sohail M.A., Gomes D.A., Hashmi A., Nagata J., Sutterwala F.S., et al. Inflammasome-mediated regulation of hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2009, 296:G1248-G1257.
35. Zhu P., Duan L., Chen J., Xiong A., Xu Q., Zhang H., et al. Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum Gene Ther 2011, 22:853-864.
36. Tsutsui H., Imamura M., Fujimoto J., Nakanishi K. The TLR4/TRIF-mediated activation of NLRP3 inflammasome underlies endotoxin-induced liver injury in mice. Gastroenterol Res Pract 2010, 2010:641865.
37. Ritter M., Gross O., Kays S., Ruland J., Nimmerjahn F., Saijo S., et al. Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. Proc Natl Acad Sci U S A 2010, 107:20459-20464.
38. Csak T., Ganz M., Pespisa J., Kodys K., Dolganiuc A., Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011, 54:133-144.
39. Ganz M., Csak T., Nath B., Szabo G. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World J Gastroenterol 2011, 17:4772-4778.
40. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
41. Ubeda C., Lipuma L., Gobourne A., Viale A., Leiner I., Equinda M., et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. JExp Med 2012, 209:1445-1456.
42. Elinav E., Strowig T., Kau A.L., Henao-Mejia J., Thaiss C.A., Booth C.J., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:745-757.
43. Nordenstedt H., White D.L., El-Serag H.B. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010, 42(Suppl.3):S206-S214.
44. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
45. Levy C., Lindor K.D. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006, 26:22-30.
46. O'Toole A., Alakkari A., Keegan D., Doherty G., Mulcahy H., O'Donoghue D. Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012, 10:439-441.
47. Ye B.D., Yang S.K., Boo S.J., Cho Y.K., Yang D.H., Yoon S.M., et al. Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea. Inflamm Bowel Dis 2011, 17:1901-1906.
48. Hashimoto E., Ideta M., Taniai M., Watanabe U., Okuda H., Nagasako K., et al. Prevalence of primary sclerosing cholangitis and other liver diseases in Japanese patients with chronic ulcerative colitis. JGastroenterol Hepatol 1993, 8:146-149.
49. Bergquist A., Montgomery S.M., Bahmanyar S., Olsson R., Danielsson A., Lindgren S., et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008, 6:939-943.
50. Bambha K., Kim W.R., Talwalkar J., Torgerson H., Benson J.T., Therneau T.M., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364-1369.
51. Sano H., Nakazawa T., Ando T., Hayashi K., Naitoh I., Okumura F., et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. JHepatobiliary Pancreat Sci 2011, 18:154-161.
52. Joo M., Abreu-e-Lima P., Farraye F., Smith T., Swaroop P., Gardner L., et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009, 33:854-862.
53. Rudolph G., Gotthardt D., Kloters-Plachky P., Kulaksiz H., Rost D., Stiehl A. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. JHepatol 2009, 51:149-155.
54. Mulder A.H., Horst G., Haagsma E.B., Limburg P.C., Kleibeuker J.H., Kallenberg C.G. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993, 17:411-417.
55. Terjung B., Herzog V., Worman H.J., Gestmann I., Bauer C., Sauerbruch T., et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998, 28:332-340.
56. Terjung B., Sohne J., Lechtenberg B., Gottwein J., Muennich M., Herzog V., et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010, 59:808-816.
57. Washington M.K. Autoimmune liver disease: overlap and outliers. Mod Pathol 2007, 20(Suppl.1):S15-S30.
58. Hopf U., Moller B., Stemerowicz R., Lobeck H., Rodloff A., Freudenberg M., et al. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 1989, 2:1419-1422.
59. Bogdanos D.P., Baum H., Grasso A., Okamoto M., Butler P., Ma Y., et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. JHepatol 2004, 40:31-39.
60. Bogdanos D.P., Baum H., Okamoto M., Montalto P., Sharma U.C., Rigopoulou E.I., et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 2005, 42:458-465.
61. Selmi C., Balkwill D.L., Invernizzi P., Ansari A.A., Coppel R.L., Podda M., et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003, 38:1250-1257.
62. Sheth S.G., Gordon F.D., Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997, 126:137-145.
63. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434-438.
64. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
65. Tolman K.G., Fonseca V., Dalpiaz A., Tan M.H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007, 30:734-743.
66. Cerda C., Perez-Ayuso R.M., Riquelme A., Soza A., Villaseca P., Sir-Petermann T., et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. JHepatol 2007, 47:412-417.
67. Caldwell S.H., Oelsner D.H., Iezzoni J.C., Hespenheide E.E., Battle E.H., Driscoll C.J. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
68. Shimada M., Hashimoto E., Taniai M., Hasegawa K., Okuda H., Hayashi N., et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. JHepatol 2002, 37:154-160.
69. Propst A., Propst T., Judmaier G., Vogel W. Prognosis in nonalcoholic steatohepatitis. Gastroenterology 1995, 108:1607.
70. Charlton M. Cirrhosis and liver failure in nonalcoholic fatty liver disease: molehill or mountain?. Hepatology 2008, 47:1431-1433.
71. Hjelkrem M.C., Torres D.M., Harrison S.A. Nonalcoholic fatty liver disease. Minerva Med 2008, 99:583-593.
72. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
73. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
74. Younossi Z.M., Stepanova M., Afendy M., Fang Y., Younossi Y., Mir H., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011, 9:524-530. e1; quiz e60.
75. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
76. Ley R.E., Backhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon J.I. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005, 102:11070-11075.
77. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
78. Muegge B.D., Kuczynski J., Knights D., Clemente J.C., Gonzalez A., Fontana L., et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 2011, 332:970-974.
79. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F., et al. Ametagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490:55-60.
80. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., Mende D.R., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
81. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.Y., Keilbaugh S.A., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334:105-108.
82. De Filippo C., Cavalieri D., Di Paola M., Ramazzotti M., Poullet J.B., Massart S., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 2010, 107:14691-14696.
83. Le Roy T., Llopis M., Lepage P., Bruneau A., Rabot S., Bevilacqua C., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2012.
84. Quigley E.M., Marsh M.N., Shaffer J.L., Markin R.S. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993, 104:286-301.
85. Carter B.A., Karpen S.J. Intestinal failure-associated liver disease: management and treatment strategies past, present, and future. Semin Liver Dis 2007, 27:251-258.
86. Nazim M., Stamp G., Hodgson H.J. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology 1989, 36:349-351.
87. Corrodi P. Jejunoileal bypass: change in the flora of the small intestine and its clinical impact. Rev Infect Dis 1984, 6(Suppl.1):S80-S84.
88. Vanderhoof J.A., Tuma D.J., Antonson D.L., Sorrell M.F. Effect of antibiotics in the prevention of jejunoileal bypass-induced liver dysfunction. Digestion 1982, 23:9-15.
89. Pappo I., Bercovier H., Berry E.M., Haviv Y., Gallily R., Freund H.R. Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide. JParenter Enteral Nutr 1992, 16:529-532.
90. Sabate J.M., Jouet P., Harnois F., Mechler C., Msika S., Grossin M., et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008, 18:371-377.
91. Miele L., Valenza V., La Torre G., Montalto M., Cammarota G., Ricci R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
92. Sajjad A., Mottershead M., Syn W.K., Jones R., Smith S., Nwokolo C.U. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005, 22:291-299.
93. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., McCarthy P.J., Grose R.H., Cummins A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
94. Basile A.S., Jones E.A. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997, 25:1303-1305.
95. Guarner C., Soriano G. Spontaneous bacterial peritonitis. Semin Liver Dis 1997, 17:203-217.
96. Campillo B., Pernet P., Bories P.N., Richardet J.P., Devanlay M., Aussel C. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol 1999, 11:755-759.
97. Thalheimer U., Triantos C.K., Samonakis D.N., Patch D., Burroughs A.K. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005, 54:556-563.
98. Husova L., Lata J., Husa P., Senkyrik M., Jurankova J., Dite P. Bacterial infection and acute bleeding from upper gastrointestinal tract in patients with liver cirrhosis. Hepatogastroenterology 2005, 52:1488-1490.
99. Bauer T.M., Steinbruckner B., Brinkmann F.E., Ditzen A.K., Schwacha H., Aponte J.J., et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001, 96:2962-2967.
100. Gunnarsdottir S.A., Sadik R., Shev S., Simren M., Sjovall H., Stotzer P.O., et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 2003, 98:1362-1370.
101. Sung J.Y., Shaffer E.A., Costerton J.W. Antibacterial activity of bile salts against common biliary pathogens. Effects of hydrophobicity of the molecule and in the presence of phospholipids. Dig Dis Sci 1993, 38:2104-2112.
102. Bajaj J.S. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010, 31:537-547.
103. Williams R. Review article: bacterial flora and pathogenesis in hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl.1):17-22.
104. Sidhu S.S., Goyal O., Mishra B.P., Sood A., Chhina R.S., Soni R.K. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011, 106:307-316.
105. Bajaj J.S., Heuman D.M., Wade J.B., Gibson D.P., Saeian K., Wegelin J.A., et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011, 140:478-487. e1.
106. Bass N.M., Mullen K.D., Sanyal A., Poordad F., Neff G., Leevy C.B., et al. Rifaximin treatment in hepatic encephalopathy. NEngl J Med 2010, 362:1071-1081.
107. Chen Y., Yang F., Lu H., Wang B., Lei D., Wang Y., et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011, 54:562-572.
108. Bajaj J.S., Ridlon J.M., Hylemon P.B., Thacker L.R., Heuman D.M., Smith S., et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012, 302:G168-G175.